Status:

COMPLETED

A Phase 1b Study of PPI-461 in Patients With HCV Genotype 1

Lead Sponsor:

Presidio Pharmaceuticals, Inc.

Conditions:

Chronic Genotype 1 Hepatitis C Virus Infection

Eligibility:

All Genders

18-65 years

Phase:

PHASE1

Brief Summary

The purpose of the study is to assess the safety, tolerability, antiviral effects, and pharmacokinetics of PPI-461 in patients with chronic hepatitis C virus genotype 1 infection.

Eligibility Criteria

Inclusion

  • Eligibility Criteria:
  • Male or female, between 18 and 65 years of age (female patients must be surgically sterile or 2 years post-menopausal and are required to take a pregnancy test)
  • Body Mass Index (BMI) 18 - 32 kg/m2
  • Chronically infected with hepatitis C genotype-1 virus
  • Serum HCV RNA \> 5 log10 IU/mL
  • No previous treatment with interferon, peginterferon, ribavirin or any investigational HCV antiviral agents
  • No history of signs or symptoms of decompensated liver disease
  • No known history of cirrhosis
  • No co-infection with HBV, HIV-1, HIV-2
  • No history of any medical condition that may interfere with absorption, distribution or elimination of study drug or with the clinical and laboratory assessments in this study
  • No history of alcohol abuse, or illicit drug use within 2 years prior to Screen, or enrollment in a methadone maintenance program (unless he/she has been enrolled in the methadone program for at least 3 months with good compliance, stable psychosocial circumstances, and no known current risks for recidivism)

Exclusion

    Key Trial Info

    Start Date :

    October 1 2010

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    June 1 2011

    Estimated Enrollment :

    24 Patients enrolled

    Trial Details

    Trial ID

    NCT01247194

    Start Date

    October 1 2010

    End Date

    June 1 2011

    Last Update

    February 3 2012

    Active Locations (11)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 3 (11 locations)

    1

    Local Institution

    Sacramento, California, United States, 95817

    2

    Local institution

    San Francisco, California, United States, 94115

    3

    Local institution

    Aarhus, Denmark

    4

    Local institution

    Copenhagen, Denmark